Analysis & ranking
PHASE 2 — Evidence and Impact Analysis
Article 1 — Chen Y et al. — cmDNA liquid biopsy for gastric cancer (PMID 42215593)
🔴 Early Cancer Detection
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Circulating microbiome DNA as a liquid biopsy signal is a genuinely novel analyte class, distinct from ctDNA/cfDNA; applying it to gastric cancer with ML integration is a meaningful methodological advance |
| Clinical Relevance | 7 | AUC 0.914 in independent validation is clinically meaningful; Stage I AUC 0.792 is encouraging but not yet at screening-threshold accuracy; China-centric cohort limits immediate global applicability |
| Population Reach | 8 | Gastric cancer is the 5th most common cancer globally and 3rd deadliest; early-stage detection gap is severe; highest burden in East Asia but globally significant |
| Implementation Speed | 5 | Requires specialized plasma microbiome extraction + ML infrastructure; regulatory pathway undefined; needs non-Asian validation before broad deployment |
| Evidence Strength | 7 | Prospective multicenter design with independent validation cohort (n=299) is solid; training/testing split appropriate; abstract-only limits assessment of methodological detail |
Key quantitative result: AUC 0.914 (overall), AUC 0.792 (Stage I), independent validation n=299 of 885 total External validation: Yes — independent multicenter validation cohort included Main limitation: China-only cohort; microbiome profiles are population/diet-dependent and may not generalize; ML model architecture undisclosed Equity implications: Benefits Asian populations most immediately where gastric cancer burden is highest; populations in Africa, Latin America, and South Asia with high gastric cancer rates may also benefit but are underrepresented in training data; Western populations underserved until validation studies are conducted Evidence Maturity: Validated (confirmed) — independent multicenter cohort qualifies; not yet practice-changing pending broader validation
Original triage_score: 8 | Phase 2 Composite: 7.1
Article 2 — González-Martos R et al. — Latent biochemical phenotypes in older adults (PMID 42215477)
🟢 Near-Term Implementable
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | ML clustering of routine labs for aging phenotyping is not entirely new, but 10-year longitudinal follow-up, sex-specific analysis, and partial independent replication elevate this above prior cross-sectional work; the Haematological phenotype thrombosis HR=7.20 signal is striking |
| Clinical Relevance | 7 | Directly actionable using labs already collected in primary care; predictive value for 10-year mortality and frailty is clinically useful; sex-specific HR=1.49 (women, Metabolic phenotype) is concrete |
| Population Reach | 9 | Older adults are the largest and fastest-growing healthcare consumer group globally; scalable to any healthcare system with routine blood testing |
| Implementation Speed | 7 | Uses universally available routine labs (CBC + biochemistry); ML clustering is deployable without new assays; primary barrier is clinical workflow integration and validation in diverse health systems |
| Evidence Strength | 7 | 10-year longitudinal cohort, n=1,491, partial independent replication in EXERNET — solid by observational standards; "partial" replication is a meaningful qualifier; abstract-only limits full appraisal |
Key quantitative result: Metabolic phenotype women HR=1.49 for 10-year mortality; Haematological phenotype men thrombosis HR=7.20 (striking, needs scrutiny) External validation: Partial — EXERNET replication cohort; Metabolic phenotype replicated; Haematological and Healthy phenotype replication status unclear Main limitation: EXERNET cohort is physically active older adults — likely healthier baseline, limiting representativeness; partial replication only; abstract-only Equity implications: Toledo Study is Spanish; generalizability to non-European, lower-income, or ethnically diverse populations is untested; routine blood panels may not be equally available in LMIC settings; sex-specific analysis is a positive equity feature Evidence Maturity: Validated (confirmed) — longitudinal with replication, though partial
Original triage_score: 8 | Phase 2 Composite: 7.4
Article 3 — Wechalekar AD et al. — Anselamimab CARES trial in AL amyloidosis (PMID 42212672)
🟠 Novel Treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Anti-amyloid fibril monoclonal antibody mechanism is distinct from plasma cell-directed therapy; kappa/lambda isotype-stratified biology emerging from a Phase 3 trial is a genuine conceptual advance for the field |
| Clinical Relevance | 7 | Primary endpoint not met overall — this is a critical constraint on clinical relevance for the full population; however, 62% ACM reduction in kappa subgroup (HR 0.38) in a disease with median survival under 6 months at Stage IIIb is clinically profound if confirmed |
| Population Reach | 5 | AL amyloidosis is rare (~10–15 per million); however, within this population the unmet need is extreme — Stage IIIa/IIIb carries mortality approaching 30–50% at 6 months; Population Reach scored relative to unmet need in the rare disease context |
| Implementation Speed | 5 | Drug not approved; primary endpoint failure means regulatory pathway is uncertain; kappa subgroup will likely require a new biomarker-selected trial before approval; JCO publication accelerates community awareness |
| Evidence Strength | 8 | Phase 3 double-blind RCT, n=406, JCO publication, international multicenter — highest design quality in the batch; kappa subgroup analysis was pre-specified but underpowered as primary endpoint; this appropriately tempers strength for that specific finding |
Key quantitative result: Overall win ratio 1.11 (p=0.332, NS); kappa subgroup HR 0.38 for ACM (p=0.012), IRR 0.29 for CVH (p=0.028), n=72 External validation: None yet; single trial; kappa subgroup is hypothesis-generating Main limitation: Primary endpoint failed; kappa subgroup was pre-specified but study not powered for it; lambda population showed no benefit; potential sponsor influence (Alexion/AstraZeneca) Equity implications: AL amyloidosis is underdiagnosed globally, especially in lower-income settings; isotype testing (kappa vs. lambda) requires laboratory infrastructure not universally available; benefits initially concentrated in high-resource specialized amyloidosis centers Evidence Maturity: Validated (for overall population — negative result); Exploratory (for kappa subgroup signal — revised downward from "Validated")
Original triage_score: 8 | Phase 2 Composite: 6.7
Article 4 — Wang L et al. — PSB202 bifunctional CD20/CD37 antibody (PMID 42216090)
🟠 Novel Treatment
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | T-cell-independent dual CD20/CD37 depletion is a genuinely first-in-class mechanism; avoiding CRS by bypassing T-cell engagement is a meaningful safety innovation |
| Clinical Relevance | 4 | Phase Ia, n=15, ORR 30% in 10 evaluable — far too early for clinical practice impact; CRS-free profile is promising but unconfirmed at scale |
| Population Reach | 6 | R/R B-NHL is a substantial patient population globally; heavily pretreated patients have very limited options |
| Implementation Speed | 2 | Phase Ia only; 5–10 years minimum to potential approval |
| Evidence Strength | 4 | Phase Ia, very small n, limited evaluable patients; abstract-only; single-cell TME data is exploratory |
Key quantitative result: ORR 30% (3/10 evaluable); 1 CR at 300mg; MTD not reached External validation: None Main limitation: n=15 (10 evaluable) is extremely small; no comparator; single-arm Phase Ia Equity implications: Heavily pretreated R/R B-NHL disproportionately lacks options in resource-limited settings; if approved, cost and access will be major barriers Evidence Maturity: Exploratory (confirmed)
Original triage_score: 7 | Phase 2 Composite: 4.7
Article 5 — Desai B et al. — Peristromal niches and T-DXd in ALK+ NSCLC (PMID 42215447)
⚪ Promising but Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 8 | Ecological niche-based explanation for residual disease, combined with exploitability of adaptive HER2 upregulation by an approved ADC, is a genuinely creative and impactful conceptual contribution |
| Clinical Relevance | 4 | Mixed model (in vivo + human tissue); T-DXd is FDA-approved making translational leap shorter, but clinical evidence in this context is absent; non-human cap applied |
| Population Reach | 6 | ALK+ NSCLC is ~3–5% of all NSCLC; NSCLC overall is one of the most common cancers globally |
| Implementation Speed | 3 | Preclinical mechanistic stage; clinical trial design needed to test T-DXd in this context |
| Evidence Strength | 5 | Nature Communications, high-quality venue; mixed species model; medium confidence classification — capped accordingly |
Key quantitative result: Qualitative mechanistic — T-DXd described as "dramatically enhancing response and suppressing relapse" in models; no specific quantitative endpoint reported in abstract External validation: Not externally validated; mechanistic study Main limitation: Mixed/in vivo models; clinical validation entirely absent; abstract-only; medium confidence classification Equity implications: ALK+ NSCLC disproportionately affects younger, never-smoker patients and is more common in Asian women; targeted therapies already face access barriers in LMICs Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 Composite: 5.3
Article 6 — Hernández-Abad I et al. — AI morphology-molecular biomarkers in hematologic malignancies (PMID 42215353)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Synthesizes an active area; no new primary data; virtual staining and interpretability framing adds some conceptual value |
| Clinical Relevance | 6 | Directly relevant for hematopathology workflow; expert-level classification claims require prospective validation in diverse settings |
| Population Reach | 7 | Hematologic malignancies broadly; AI morphology improvements affect all patients requiring bone marrow/blood smear interpretation |
| Implementation Speed | 5 | Review maps a path; actual implementation requires prospective validation and regulatory clearance |
| Evidence Strength | 5 | Systematic review with no primary data; commercial author COIs noted |
Key quantitative result: No new primary data; synthesis of literature findings External validation: N/A (review) Main limitation: No primary data; COI from Spotlab-affiliated authors; abstract-only Equity implications: AI morphology could democratize expert-level diagnosis globally but requires validated systems; risk of training data bias in underrepresented populations Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 Composite: 5.7
Article 7 — Wei Q et al. — Deep learning-radiomics for rectal cancer LNM prediction (PMID 42215698)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Multimodal DL-radiomics for rectal cancer LNM is an active space; interpretability feature and post-CRT specific application add moderate novelty |
| Clinical Relevance | 6 | LNM prediction directly impacts surgical extent decisions; multicenter validation is clinically meaningful |
| Population Reach | 6 | Colorectal cancer is 3rd most common globally; locally advanced rectal cancer post-CRT surgical decisions affect a substantial subset |
| Implementation Speed | 5 | Multicenter validated; interpretability aids deployment; regulatory pathway and EHR integration needed |
| Evidence Strength | 6 | Multicenter diagnostic validation is appropriate design; sample size unknown from abstract; medium classification confidence |
Key quantitative result: Not specified in abstract beyond "multicenter external validation achieved" External validation: Yes — multicenter external validation included Main limitation: Sample size unknown; abstract-only; China-centric cohort; performance metrics not specified Equity implications: Rectal cancer surgical planning improvements are most accessible in high-resource centers; AI tool accessibility in LMIC settings is uncertain Evidence Maturity: Validated (confirmed — multicenter)
Original triage_score: 6 | Phase 2 Composite: 5.6
Article 8 — Sun M et al. — Metformin vs DPP-4i and parkinsonism risk (PMID 42216231)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Metformin neuroprotection hypothesis is well-established; novel contribution is rigorous landmark design addressing immortal time bias in the largest cohort to date |
| Clinical Relevance | 6 | Negative primary result is clinically informative — clarifies a popular hypothesis; exploratory 10-year signal insufficient to change practice |
| Population Reach | 9 | T2DM affects ~500 million globally; metformin is the most prescribed diabetes drug worldwide |
| Implementation Speed | 4 | Negative primary result means no immediate practice change; exploratory signal would require prospective RCT |
| Evidence Strength | 6 | Rigorous landmark design, large n=151,070, active comparator PS-matched; TriNetX retrospective RWE limitations apply |
Key quantitative result: Overall aHR 0.97 (95%CI 0.87–1.09, NS); 10-year landmark aHR 0.85 (p=0.015, exploratory); n=151,070 External validation: Not externally validated Main limitation: Retrospective RWE; TriNetX coding heterogeneity; survivorship bias in 10-year landmark; residual confounding Equity implications: T2DM disproportionately affects lower-income and minority populations; negative result prevents misguided neuroprotection-based prescribing; global applicability of TriNetX cohort depends on network composition Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 Composite: 5.9
Article 9 — Wang Y & Yuan Z — CRP-to-albumin ratio and HF mortality (PMID 42216136)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | CAR as a HF prognostic marker is not new; this meta-analysis consolidates existing data but does not introduce new biology |
| Clinical Relevance | 5 | If validated prospectively, CAR could be a rapid, low-cost HF risk stratification tool; current evidence is insufficient for routine use |
| Population Reach | 8 | Heart failure affects ~64 million globally; a simple, widely available risk marker has high reach potential |
| Implementation Speed | 4 | CRP and albumin are universally available; however, prospective validation required before clinical adoption |
| Evidence Strength | 5 | 12 cohort studies, n=6,377; I²=66% moderate heterogeneity; prospective RR substantially weaker (1.45 vs 2.50 retrospective) — concerning |
Key quantitative result: RR=2.34 (95%CI 1.86–2.93) overall; prospective RR=1.45; retrospective RR=2.50; I²=66% External validation: N/A (meta-analysis of observational studies) Main limitation: High heterogeneity; retrospective/prospective discrepancy strongly suggests publication bias or confounding in retrospective studies; abstract-only Equity implications: CAR components are available in nearly all health settings globally; low-cost marker could benefit resource-limited populations if validated Evidence Maturity: Exploratory (confirmed)
Original triage_score: 6 | Phase 2 Composite: 5.1
Article 10 — Chatrathi AR et al. — Cardiotoxicity in multiple myeloma therapies (PMID 42215456)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Convergent cardiotoxicity mechanisms across MM therapy classes is a useful synthesis; no new primary data |
| Clinical Relevance | 6 | Directly relevant for MM prescribers and cardio-oncologists; GLS + troponin monitoring guidance is actionable |
| Population Reach | 6 | Multiple myeloma affects ~160,000 new cases/year globally; growing survivor population |
| Implementation Speed | 5 | Monitoring protocols are actionable now; omics-based risk models are not yet validated |
| Evidence Strength | 4 | Narrative/systematic review; no primary data; abstract-only |
Key quantitative result: None — review article External validation: N/A Main limitation: No primary data; review design; abstract-only Equity implications: MM cardiotoxicity monitoring is most feasible in specialized centers; access disparities in cardio-oncology exist globally Evidence Maturity: Exploratory (confirmed)
Original triage_score: 5 | Phase 2 Composite: 5.3
Article 11 — Chen J et al. — Molecular subtyping of gastric cancer (PMID 42216188)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | TCGA/ACRG classifications are well-established; this is a synthesis review |
| Clinical Relevance | 5 | Clinically useful reference for precision GC treatment; complements Article 1 in context |
| Population Reach | 7 | Gastric cancer global burden is high |
| Implementation Speed | 5 | Molecular subtyping already partially implemented in some centers |
| Evidence Strength | 3 | Review only; no primary data |
Original triage_score: 5 | Phase 2 Composite: 4.7 Evidence Maturity: Exploratory (confirmed)
Article 12 — Chen J et al. — MSTM-Net prostate cancer segmentation (PMID 42215932)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Swin Transformer-Mamba architecture combination is novel; ~4% Dice improvement is incremental |
| Clinical Relevance | 3 | No clinical validation; benchmark dataset only |
| Population Reach | 7 | Prostate cancer is the most common cancer in men globally |
| Implementation Speed | 3 | Requires prospective clinical validation before deployment |
| Evidence Strength | 5 | Validated on two established benchmark datasets; cross-dataset generalization demonstrated; clinical validation absent |
Original triage_score: 5 | Phase 2 Composite: 4.5 Evidence Maturity: Exploratory (confirmed)
Article 13 — Mohr AE et al. — P4 medicine multi-omics framework (PMID 42216189)
⚪ Promising but Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Digital twin + blockchain for precision medicine is conceptually current but not empirically new |
| Clinical Relevance | 3 | Primarily conceptual; preliminary metabolomics data (n=2,072) is underpowered for conclusions |
| Population Reach | 6 | Population-level precision medicine has broad theoretical reach |
| Implementation Speed | 2 | Conceptual framework; significant validation, regulatory, and infrastructure barriers |
| Evidence Strength | 3 | Perspective with commercial COI; preliminary metabolomics only; medium confidence |
Original triage_score: 5 | Phase 2 Composite: 3.8 Evidence Maturity: Exploratory (confirmed); conservative scoring applied per low-medium confidence classification
Article 14 — Kostoulas C et al. — Exome sequencing in preventive genetics (PMID 42212615)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | Expanding exome sequencing to preventive use is an active area; findings unclear from abstract |
| Clinical Relevance | 4 | Potentially actionable for rare disease prevention; details inaccessible |
| Population Reach | 5 | Rare disease genomic screening has wide theoretical reach but limited near-term scale |
| Implementation Speed | 3 | Requires infrastructure, cost reduction, and policy framework |
| Evidence Strength | 3 | Low confidence classification; sample size unknown; abstract-only |
Original triage_score: 5 | Phase 2 Composite: 3.9 Evidence Maturity: Exploratory (confirmed); conservative scoring applied per low classification confidence
Article 15 — Ren Y et al. — HER2+ exosome fluorescent probe platform (PMID 42215863)
⚪ Promising but Preliminary
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 7 | Peptide-based multivariate fluorescent sensing for HER2+ exosomes is a creative analytical chemistry advance |
| Clinical Relevance | 3 | In vitro / cell-line primary validation; pilot human samples only; non-human cap applies |
| Population Reach | 7 | HER2+ breast cancer affects hundreds of thousands annually |
| Implementation Speed | 2 | Proof-of-concept stage; 10+ years from clinical deployment |
| Evidence Strength | 4 | Analytical Chemistry venue is high quality; mixed species model; limited patient data |
Original triage_score: 5 | Phase 2 Composite: 4.6 Evidence Maturity: Exploratory (confirmed)
Article 16 — Xie J et al. — SQLE biomarker in hepatocellular carcinoma (PMID 42215741)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 6 | SQLE in HCC is emerging; spatial transcriptomics validation adds methodological novelty |
| Clinical Relevance | 5 | Multi-cohort validated biomarker is clinically meaningful; therapeutic targetability of SQLE requires further work |
| Population Reach | 7 | HCC is the 6th most common cancer globally and 3rd leading cause of cancer death |
| Implementation Speed | 4 | Biomarker validation stage; functional/therapeutic validation needed |
| Evidence Strength | 5 | Multi-cohort + spatial transcriptomics is methodologically strong; sample size unknown; medium confidence |
Original triage_score: 5 | Phase 2 Composite: 5.6 Evidence Maturity: Validated (confirmed for biomarker association)
Article 17 — Joseph J et al. — AVP deficiency variant catalogue (PMID 42212497)
🟡 Underserved Population
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Novel variant identification in a rare disease; curated catalogue has community value |
| Clinical Relevance | 5 | Directly improves genetic diagnosis for a rare but treatable condition; treatment (desmopressin) already exists |
| Population Reach | 3 | Ultra-rare condition; Population Reach scored relative to unmet diagnostic need in rare disease context |
| Implementation Speed | 6 | Variant catalogues are immediately usable by clinical genetics labs |
| Evidence Strength | 4 | Case study + curation; medium confidence; small scale |
Original triage_score: 4 | Phase 2 Composite: 4.5 Evidence Maturity: Exploratory (confirmed)
Article 18 — Qiao T et al. — PET/CT metabolic parameters in ALK+ NSCLC (PMID 42216213)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 4 | SUVmax + tumor size combination for LNM prediction is not novel; ALK+ NSCLC-specific focus adds modest novelty |
| Clinical Relevance | 5 | AUC 0.81 for LNM and TLG for occult LNM have direct surgical planning relevance |
| Population Reach | 5 | ALK+ NSCLC is a small but well-defined subgroup |
| Implementation Speed | 4 | PET/CT is widely available in high-resource settings; needs prospective validation |
| Evidence Strength | 5 | Retrospective, single-center, n=157; limitations constrain confidence |
Original triage_score: 5 | Phase 2 Composite: 4.8 Evidence Maturity: Exploratory (confirmed)
Article 19 — Tan J et al. — HRQoL and medication discrepancies in T2DM (PMID 42216205)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 3 | Medication discrepancy prevalence in care transitions is a known issue; non-monotonic HRQoL finding is modestly interesting |
| Clinical Relevance | 4 | Identifies a care transition risk but cross-sectional design prevents causal inference |
| Population Reach | 7 | T2DM affects hundreds of millions; care transition safety is broadly relevant |
| Implementation Speed | 5 | Cross-sectional findings suggest intervention targets but require intervention design |
| Evidence Strength | 4 | Cross-sectional survey; single city; n=552; limited generalizability |
Original triage_score: 4 | Phase 2 Composite: 4.6 Evidence Maturity: Exploratory (confirmed)
Article 20 — Galasso I et al. — Precision medicine vs. public health (PMID 42215252)
⬜ Standard
| Dimension | Score | Rationale |
|---|---|---|
| Scientific Novelty | 5 | Three-configuration framework for PM-SDH relationship is a useful conceptual contribution |
| Clinical Relevance | 3 | Policy/sociological framing; indirect clinical impact |
| Population Reach | 8 | PM equity implications affect population-level health globally |
| Implementation Speed | 3 | Policy change is slow; conceptual framework is the output |
| Evidence Strength | 5 | Qualitative/mixed methods; appropriate for research question; medium confidence |
Original triage_score: 4 | Phase 2 Composite: 4.7 Evidence Maturity: Exploratory (confirmed)
PHASE 3 — Ranking
Conflict Check
No direct contradictions across articles. Articles 1 and 11 are complementary (gastric cancer detection and molecular subtyping). Articles 5 and 18 both address ALK+ NSCLC from different angles (mechanistic resistance vs. staging) without conflict. Article 8's negative metformin-parkinsonism result does not conflict with other articles. No within-batch disagreements requiring resolution.
Composite Impact Score Calculation
Weighting: Clinical Relevance (30%) + Population Reach (25%) + Scientific Novelty (20%) + Implementation Speed (15%) + Evidence Strength (10%)
| Rank | # | PMID | Title (short) | Clin. Rel. ×0.30 | Pop. Reach ×0.25 | Sci. Novelty ×0.20 | Impl. Speed ×0.15 | Evid. Strength ×0.10 | Impact Score | Triage Score | Flag |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 42215477 | Latent biochemical phenotypes, older adults | 7×0.30=2.10 | 9×0.25=2.25 | 7×0.20=1.40 | 7×0.15=1.05 | 7×0.10=0.70 | 7.50 | 8 | 🟢 |
| 2 | 1 | 42215593 | cmDNA liquid biopsy, gastric cancer | 7×0.30=2.10 | 8×0.25=2.00 | 8×0.20=1.60 | 5×0.15=0.75 | 7×0.10=0.70 | 7.15 | 8 | 🔴 |
| 3 | 3 | 42212672 | Anselamimab CARES trial, AL amyloidosis | 7×0.30=2.10 | 5×0.25=1.25 | 8×0.20=1.60 | 5×0.15=0.75 | 8×0.10=0.80 | 6.50 | 8 | 🟠 |
| 4 | 8 | 42216231 | Metformin vs DPP-4i, parkinsonism risk | 6×0.30=1.80 | 9×0.25=2.25 | 5×0.20=1.00 | 4×0.15=0.60 | 6×0.10=0.60 | 6.25 | 6 | ⬜ |
| 5 | 5 | 42215447 | Peristromal niches, T-DXd, ALK+ NSCLC | 4×0.30=1.20 | 6×0.25=1.50 | 8×0.20=1.60 | 3×0.15=0.45 | 5×0.10=0.50 | 5.25 | 6 | ⚪ |
| 6 | 6 | 42215353 | AI morphology-molecular biomarkers, hem. malignancies | 6×0.30=1.80 | 7×0.25=1.75 | 5×0.20=1.00 | 5×0.15=0.75 | 5×0.10=0.50 | 5.80 | 6 | ⬜ |
| 7 | 16 | 42215741 | SQLE biomarker, hepatocellular carcinoma | 5×0.30=1.50 | 7×0.25=1.75 | 6×0.20=1.20 | 4×0.15=0.60 | 5×0.10=0.50 | 5.55 | 5 | ⬜ |
| 8 | 7 | 42215698 | DL-radiomics, rectal cancer LNM | 6×0.30=1.80 | 6×0.25=1.50 | 5×0.20=1.00 | 5×0.15=0.75 | 6×0.10=0.60 | 5.65 | 6 | ⬜ |
| 9 | 9 | 42216136 | CRP-albumin ratio, heart failure mortality | 5×0.30=1.50 | 8×0.25=2.00 | 4×0.20=0.80 | 4×0.15=0.60 | 5×0.10=0.50 | 5.40 | 6 | ⬜ |
| 10 | 10 | 42215456 | Cardiotoxicity in MM therapies (review) | 6×0.30=1.80 | 6×0.25=1.50 | 5×0.20=1.00 | 5×0.15=0.75 | 4×0.10=0.40 | 5.45 | 5 | ⬜ |
| 11 | 4 | 42216090 | PSB202 CD20/CD37, R/R B-NHL | 4×0.30=1.20 | 6×0.25=1.50 | 8×0.20=1.60 | 2×0.15=0.30 | 4×0.10=0.40 | 5.00 | 7 | 🟠 |
| 12 | 18 | 42216213 | PET/CT metabolic, ALK+ NSCLC LNM | 5×0.30=1.50 | 5×0.25=1.25 | 4×0.20=0.80 | 4×0.15=0.60 | 5×0.10=0.50 | 4.65 | 5 | ⬜ |
| 13 | 11 | 42216188 | Molecular subtyping, gastric cancer (review) | 5×0.30=1.50 | 7×0.25=1.75 | 3×0.20=0.60 | 5×0.15=0.75 | 3×0.10=0.30 | 4.90 | 5 | ⬜ |
| 14 | 15 | 42215863 | HER2+ exosome fluorescent probe | 3×0.30=0.90 | 7×0.25=1.75 | 7×0.20=1.40 | 2×0.15=0.30 | 4×0.10=0.40 | 4.75 | 5 | ⚪ |
| 15 | 20 | 42215252 | Precision medicine vs. public health | 3×0.30=0.90 | 8×0.25=2.00 | 5×0.20=1.00 | 3×0.15=0.45 | 5×0.10=0.50 | 4.85 | 4 | ⬜ |
| 16 | 17 | 42212497 | AVP deficiency variant catalogue | 5×0.30=1.50 | 3×0.25=0.75 | 5×0.20=1.00 | 6×0.15=0.90 | 4×0.10=0.40 | 4.55 | 4 | 🟡 |
| 17 | 12 | 42215932 | MSTM-Net prostate segmentation | 3×0.30=0.90 | 7×0.25=1.75 | 5×0.20=1.00 | 3×0.15=0.45 | 5×0.10=0.50 | 4.60 | 5 | ⬜ |
| 18 | 19 | 42216205 | HRQoL and medication discrepancies, T2DM | 4×0.30=1.20 | 7×0.25=1.75 | 3×0.20=0.60 | 5×0.15=0.75 | 4×0.10=0.40 | 4.70 | 4 | ⬜ |
| 19 | 14 | 42212615 | Exome sequencing, preventive genetics | 4×0.30=1.20 | 5×0.25=1.25 | 4×0.20=0.80 | 3×0.15=0.45 | 3×0.10=0.30 | 4.00 | 5 | ⬜ |
| 20 | 13 | 42216189 | P4 medicine multi-omics framework | 3×0.30=0.90 | 6×0.25=1.50 | 5×0.20=1.00 | 2×0.15=0.30 | 3×0.10=0.30 | 4.00 | 5 | ⚪ |
Ranking Justifications
#1 — González-Martos R et al., NPJ Aging (PMID 42215477) | Impact: 7.50 | Triage: 8 | 🟢 This study earns the top spot on the strength of its combination of near-term implementability with genuine longitudinal evidence. Using only routine blood biomarkers already collected in primary care globally — no new assays, no specialized platforms — an ML clustering approach stratifies a population of 1,491 older adults into three biochemical phenotypes that predict 10-year all-cause mortality, frailty, and specific disease events, with partial independent replication. The Haematological phenotype's thrombosis HR=7.20 in men, if replicated, would be a clinically explosive finding. The study's 10-year follow-up horizon and sex-specific analysis reflect methodological maturity. The core barrier to #1 is that replication was only partial and the EXERNET comparison cohort is physically active and thus systematically healthier than a general older adult population — a meaningful generalizability gap. Nonetheless, this represents the batch's best intersection of breadth of potential impact, study rigor, and near-zero additional implementation cost.
Why it matters: If validated broadly, a standard blood panel drawn at any routine clinic visit could risk-stratify every older adult for mortality trajectory, frailty, and organ-specific disease — enabling targeted prevention at population scale without a single new test.
#2 — Chen Y et al., NPJ Precision Oncology (PMID 42215593) | Impact: 7.15 | Triage: 8 | 🔴 The circulating microbiome DNA approach to gastric cancer detection is methodologically novel and clinically urgent. Gastric cancer kills ~770,000 people annually — overwhelmingly because it is caught late — and no scalable, non-endoscopic early detection tool currently exists for use in non-endemic populations. The AUC 0.914 in an independent multicenter validation cohort of 299 patients is strong, and the Stage I AUC of 0.792 is encouraging, though below screening-threshold precision. The critical limitation is cohort geography: training and validation were exclusively Chinese, and gut microbiome profiles are substantially shaped by diet, ethnicity, and antibiotic exposure. This study ranks second rather than first primarily because of lower implementation speed and greater validation burden before global deployment.
Why it matters: Circulating microbiome DNA could become a new class of liquid biopsy analyte, potentially enabling early cancer detection via a blood draw in settings where endoscopy is not routinely accessible.
#3 — Wechalekar AD et al., JCO (PMID 42212672) | Impact: 6.50 | Triage: 8 | 🟠 The CARES trial earns third on the strength of its study design (Phase 3 RCT, double-blind, n=406, JCO publication) and the magnitude of the kappa subgroup signal (HR 0.38 for all-cause mortality). It is important to be direct: the primary endpoint was not met (win ratio 1.11, p=0.332), and the kappa benefit is hypothesis-generating, not practice-changing. However, in AL amyloidosis Stage IIIa/IIIb — where median survival can be measured in months — a 62% mortality reduction in any pre-specified subgroup is a signal the field cannot ignore. The clear isotype-stratified biology (benefit in kappa, none in lambda) gives this a biologically plausible framework for a targeted follow-up trial. The high Evidence Strength score (8) reflects the trial design quality; the moderate composite score reflects the primary failure and subgroup caution.
Why it matters: For a disease where advanced-stage patients have almost no good options, a biomarker-stratified trial design based on light chain isotype could unlock an entirely new class of anti-amyloid therapy — but only if the kappa signal is prospectively confirmed.
Rankings 4–20 follow the order in the composite scoring table above. Articles 6, 7, 8, and 10 are closely bunched (5.40–5.80) and are best treated as a tier of "clinically relevant but not yet practice-informing" entries. Articles 13, 17, 19, and 20 represent context and resource value for the pipeline but limited near-term clinical impact.